Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AB-110 |
Synonyms | |
Therapy Description |
AB-110 is a preparation of umbilical cord blood-derived CD34-positive hematopoietic progenitor cells mixed with endothelial cells engineered to express the adenovirus E4ORF1 gene, potentially resulting in increased engraftment upon transplantation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AB-110 | CD34-positive Enriched HPCs Mixed with Engineered Human ECs AB-110 | AB-110 is a preparation of umbilical cord blood-derived CD34-positive hematopoietic progenitor cells mixed with endothelial cells engineered to express the adenovirus E4ORF1 gene, potentially resulting in increased engraftment upon transplantation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03483324 | Phase I | AB-110 | Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation | Completed | USA | 0 |